Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood
✍ Scribed by David A. Cabral; América G. Uribe; Susanne Benseler; Kathleen M. O'Neil; Philip J. Hashkes; Gloria Higgins; Andrew S. Zeft; Daniel J. Lovell; Daniel J. Kingsbury; Anne Stevens; Deborah McCurdy; Peter Chira; Leslie Abramson; Thaschawee Arkachaisri; Sarah Campillo; Anne Eberhard; Aimee O. Hersh; Adam M. Huber; Susan Kim; Marisa Klein-Gitelman; Deborah M. Levy; Suzanne C. Li; Thomas Mason; Esi Morgan DeWitt; Eyal Muscal; Lorien Nassi; Andreas Reiff; Kenneth Schikler; Nora G. Singer; Dawn Wahezi; Amy Woodward
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 140 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
To compare the criteria for Wegener's granulomatosis (WG) of the American College of Rheumatology (ACR) with those of the European League Against Rheumatism/Pediatric Rheumatology European Society (EULAR/PRES) in a cohort of children with WG and other antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAVs), and to describe the interval to diagnosis, presenting features, and initial treatment for WG.
Methods
Eligible patients had been diagnosed by site rheumatologists (termed the “MD diagnosis”) since 2004. This diagnosis was used as a reference standard for sensitivity and specificity testing of the 2 WG classification criteria. Descriptive analyses were confined to ACR‐classified WG patients.
Results
MD diagnoses of 117 patients (82 of whom were female) were WG (n = 76), microscopic polyangiitis (n = 17), ANCA‐positive pauci‐immune glomerulonephritis (n = 5), Churg‐Strauss syndrome (n = 2), and unclassified vasculitis (n = 17). The sensitivities of the ACR and EULAR/PRES classification criteria for WG among the spectrum of AAVs were 68.4% and 73.6%, respectively, and the specificities were 68.3% and 73.2%, respectively. Two more children were identified as having WG by the EULAR/PRES criteria than by the ACR criteria. For the 65 ACR‐classified WG patients, the median age at diagnosis was 14.2 years (range 4–17 years), and the median interval from symptom onset to diagnosis was 2.7 months (range 0–49 months). The most frequent presenting features by organ system were constitutional (89.2%), pulmonary (80.0%), ear, nose, and throat (80.0%), and renal (75.4%). Fifty‐four patients (83.1%) commenced treatment with the combination of corticosteroids and cyclophosphamide, with widely varying regimens; the remainder received methotrexate alone (n = 1), corticosteroids alone (n = 4), or a combination (n = 6).
Conclusion
The EULAR/PRES criteria minimally improved diagnostic sensitivity and specificity for WG among a narrow spectrum of children with AAVs. Diagnostic delays may result from poor characterization of childhood WG. Initial therapy varied considerably among participating centers.
📜 SIMILAR VOLUMES
## Objective: To examine the safety of mycophenolate mofetil (mmf) for remission maintenance in patients with wegener's granulomatosis (wg) who had been treated with daily cyclophosphamide (cyc) and glucocorticoids to induce remission. ## Methods: Fourteen patients were treated for active wg usin
## Abstract ## Objective The precipitating event(s) that triggers Wegener's granulomatosis (WG) is unknown. Cytokines, costimulatory molecules, and counterregulatory molecules control the quality and intensity of immune responses. Thus, they are relevant candidates for genetic studies of immune dy